erythrocyte receptor (sialoadhesin)

sialic acid-binding receptor of tissue macrophages; specifically recognizes the oligosaccharide sequence Neu5Acalpha2--3Galbeta1--3GalNAc in either sialoglycoproteins or gangliosides; RefSeq (mouse); NM_023068 (human); do not confuse with CD2 which has also been known as Sheep Red Blood Cell Receptor

Also Known As:

Networked: 121 relevant articles (0 outcomes, 13 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Crocker, Paul R: 8 articles (11/2015 - 11/2002)
2.	Nauwynck, Hans J: 5 articles (01/2013 - 11/2008)
3.	Delputte, Peter L: 5 articles (01/2013 - 11/2008)
4.	Martinez-Picado, Javier: 4 articles (11/2015 - 01/2012)
5.	Izquierdo-Useros, Nuria: 4 articles (11/2015 - 01/2012)
6.	Van Gorp, Hanne: 4 articles (01/2013 - 12/2008)
7.	Keppler, Oliver T: 3 articles (11/2015 - 01/2012)
8.	Erikson, Elina: 3 articles (11/2015 - 01/2012)
9.	Pino, Maria: 3 articles (11/2015 - 01/2012)
10.	Kräusslich, Hans-Georg: 3 articles (01/2015 - 01/2012)

Related Diseases

1.	Infection 04/01/2015 - "Our findings help to explain PRRSV infection of cells lacking sialoadhesin and provide a glycan database to facilitate molecular structural studies of PRRSV. " 06/12/2015 - "Sialoadhesin is either unnecessary for infection or may function as an accessory protein. " 06/12/2015 - "Progress has been made to shed light on the interactions between cells and PRRSV, and this review describes the advances and current understanding of the entry of PRRSV to cells with a particular focus on the role of CD163 and sialoadhesin for infection and PRRSV pathogenesis. " 03/06/2015 - "CD163 and sialoadhesin had been reported as the two receptors for porcine reproductive and respiratory syndrome virus (PRRSV) infection. " 01/01/2015 - "Siglec-1 on myeloid cells could fuel novel CD4(+) T-cell infections and contribute to HIV-1 dissemination in vivo."
2.	Neoplasms (Cancer) 12/01/1999 - "In conclusion, while SER+ macrophages are greatly decreased in bone marrow from ET bearers, this is not due to a down-regulation of sialoadhesin expression, nor to an impairment of sialoadhesin-inducing factor or to the presence of sialoadhesin-binding moieties of tumor origin, but, more likely, to a decrease of fully mature macrophages." 12/01/1999 - "Tumor progression does not impair the sialoadhesin-inducing activity of ET-bearing sera, or the ability of SER- macrophages (e.g. " 12/01/1999 - "Tumor growth is often associated with marked alterations of myelopoiesis and impairment of T cell activation; yet the expression of sialoadhesin in macrophages derived from tumor bearers has not been addressed. " 12/01/1999 - "Sialoadhesin expression by bone marrow macrophages derived from Ehrlich-tumor-bearing mice." 06/01/1999 - "Cell surface sialylation is an important component of many cellular adhesive interactions, both as ligand-promoting interactions, as occurs in selectin and sialoadhesin-mediated adhesion, and for reducing cell adhesion as in some cancer cells. "
3.	Insulin Resistance 01/01/2000 - "Our study was aimed at determining whether beneficial modification of carbohydrate metabolism can be obtained after a short-term training program and whether it is associated with an increase in binding and degradation of (125)I-insulin by erythrocyte receptors that suggests a decrease in insulin resistance. " 10/01/1996 - "We evaluated their physical efficiency (VO2max), body consistency, blood lipid profile the level of non-enzymatic glycosylation of protein, insulinemia, and insulin resistance measured by the binding of 125I-Insulin to erythrocyte receptors. " 05/01/1986 - "We did not find any argument in favor of the development of a state of insulin resistance in women using these compounds, because erythrocyte receptor binding was not modified and plasma insulin responses to glucose were decreased. " 03/01/1981 - "Therapy with tolbutamide and reduced insulin administration resulted in restoration of erythrocyte receptor binding, clinical resolution of the insulin resistance, and amelioration of hyperglycemia. "
4.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/15/1994 - "An unusual neoplasm, best classified as a B-cell chronic lymphocytic leukemia on the basis of cytofluorographic, immunohistologic, and gene rearrangement analysis also co-expressed the T-cell associated marker CD2 (sheep erythrocyte receptor), but without other cell markers restricted to T cells. " 05/01/1984 - "The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) was used for the induction of in vitro differentiation in primary cultures of chronic lymphocytic leukemia cells to study its effects on B-cell antigens [surface IgG, HLA-DR, and the mouse erythrocyte receptor (MR)] and on T-cell antigens [T65 and Lyt-3 (sheep erythrocyte receptor)] found on these cells. "
5.	Melanoma (Melanoma, Malignant) 02/01/1989 - "The infected erythrocyte receptor for thrombospondin was destroyed by mild trypsinization, as was the receptor for melanoma cells. " 08/27/1993 - "Several lines of evidence in the present study indicate that the Duffy blood group antigen is the erythrocyte receptor for the chemokines interleukin-8 (IL-8) and melanoma growth stimulatory activity (MGSA). "

Related Drugs and Biologics

1.	sialic acid binding Ig-like lectin
2.	Insulin (Novolin)
3.	Antigens
4.	Immunoglobulins (Immunoglobulin)
5.	N-Acetylneuraminic Acid (Sialic Acid)
6.	Chemokines
7.	Surface Antigens (Surface Antigen)
8.	mouse erythrocyte receptor
9.	Interleukin-8 (Interleukin 8)
10.	Cytokines

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Transplantation (Transplant Recipients)